Next Generation Sequencing on the European Growth Path
News Jan 26, 2011
New analysis from Frost & Sullivan finds that the market for Next Generation Sequencing earned revenues of $746 million in 2010 and estimates this to reach $3 billion by 2017 worldwide.
“Key applications previously performed by Microarrays are now being replaced by Next Generation Sequencers,” observes Frost & Sullivan Research Analyst, Ms. Divyaa Ravishankar. “At the same time, governments encourage the uptake of the NGS technology by facilitating a steady stream of funding.”
Both suppliers and end users have shown immense interest in driving the technology towards diagnostics applications, where it is expected to play a significant role in the next two years. However, the research realm is harnessing most benefit of Next Generation Sequencing.
The most important challenges for the technology to remain successful though, is the increase in data volume, which requires efficient data management systems as well as the interpretation and validation of new and complex findings. In order to be able to cope with the plethora of information generated through NGS, new bioinformatic software and tools are necessary. Suppliers are therefore trying to close strategic partnerships with companies offering bioinformatics solutions.
“The growing dynamism and inventiveness has resulted in the rapid uptake of Next Generation Sequencing Technology,” says Ms. Ravishankar. “Near-term challenges will be the development of robust and extensive protocols for generating sequencing libraries, building effective new approaches for the purpose of data analysis as well as lowering the cost to sequence a human genome.” She concludes: “NGS enables a comprehensive analysis of genomes, transcriptomes, interactomes and will become an inexpensive and a widespread tool.”
Frost & Sullivan has organised an on-demand webinar, entitled European Next Generation Sequencing – From Present to Future. The webinar summarises Ms. Ravishankar’s findings by giving an introduction into the current state of the market, presenting an analysis of latest trends and developments, as well as giving a snapshot of the geographical distribution of labs in Europe as well as worldwide.
Highlights of the webinar also include an analysis of end user perspectives based on technological factors, applications based on NGS in demand, and a comparative analysis of platforms like HiSeq 2000, Ilumina GA IIx, Solid 3 Plus, Solid 4 hq, 454 GS FLX Ti. The latter takes performance factors into consideration, e.g. reagent costs incurred, expenditure in data management tools, and the ease of operation standards.
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.